Timothy J. Casey Attorney at Law
Representing Clients In Phoenix And Communities Throughout Arizona
602-842-6210

EpiPen failure reports have increased in the past few years

Some people in Arizona have severe allergies and rely on EpiPens to stop anaphylactic reaction. Unfortunately, there have been reports of EpiPen failures that have resulted in injuries and deaths.

According to the federal Food and Drug Administration, there have been 228 reports of EpiPen failures from January 2017 through September 2017. During that same time period, seven people died as a result of the failures, and another 35 were hospitalized. The number of reported failures has substantially increased over the last few years. For example, there were four reported failures in 2012, 12 reported failures in 2013 and 67 reported failures in 2014.

The FDA reports that some cases involved injectors that did not function correctly while others involved epinephrine leaking out of the pens. Mylan, the company that manufacturers the pens, denied that there are any defects in the EpiPens. The company famously came under fire in the last year for increasing the price of the life-saving pens from $50 per pen to $600 for a two-pack of them.

When consumers use products in the manner in which they are intended to be used, the products should be expected to work. When they have defects, the people who use them may suffer serious injuries or deaths. Victims of EpiPen failures or the families of those who have been killed may want to talk to experienced personal injury attorneys who accept products liability cases. The lawyers may help their clients to recover damages in amounts that fairly compensate them for their resulting losses.

No Comments

Leave a comment
Comment Information

Contact The Firm

Bold labels are required.

Contact Information
disclaimer.

The use of the Internet or this form for communication with the firm or any individual member of the firm does not establish an attorney-client relationship. Confidential or time-sensitive information should not be sent through this form.

close

Privacy Policy